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Abstract: Randomized controlled trials have suggested that vitamin D supplementation can prevent
asthma and chronic obstructive pulmonary disease (COPD) exacerbations. For COPD, the benefit
appears to be limited to individuals with baseline 25-hydroxyvitamin D (25OHD) levels <25 nmol/L.
We performed a post hoc analysis of data from a randomized, double-blinded, placebo-controlled
trial to investigate the effect that monthly, high-dose vitamin D supplementation (versus placebo)
had on older adults with asthma and/or COPD. Specifically, we investigated whether vitamin D
supplementation prevented exacerbations of these conditions. Participants were randomly assigned
either to an initial oral dose of 200,000 IU vitamin D3 followed by 100,000 IU monthly or to placebo,
with an average follow-up period of 3.3 years. Among the 5110 participants, 775 had asthma or COPD
at the beginning of the study, and were eligible for inclusion in this analysis. Exacerbations were
defined by the prescription of a short-burst of oral corticosteroids. The mean age of the participants
was 67 years old, and 56% were male. The mean baseline blood 25OHD level was 63 nmol/L; 2.3%
were <25 nmol/L. Overall, we found that vitamin D supplementation did not affect the exacerbation
risk (hazard ratio 1.08; 95%CI 0.84–1.39). Among those with baseline 25OHD <25 nmol/L, however,
the hazard ratio was 0.11 (95%CI 0.02–0.51); p for interaction = 0.001. Although monthly vitamin
D supplementation had no overall impact on risk of exacerbations of asthma or COPD, we found
evidence of a probable benefit among those with severe vitamin D deficiency.
Keywords: asthma; chronic obstructive pulmonary disease; exacerbations; oral corticosteroids;
randomized controlled trial; supplement; vitamin D
1. Introduction
Among older adults, asthma and chronic obstructive pulmonary disease (COPD) are
two major obstructive airway diseases that can be difficult to distinguish, and that may
coexist as asthma-COPD overlap syndrome [1]. Both are chronic diseases characterized by
periodic exacerbations, which are usually triggered by respiratory virus infections [2]. The
treatment of asthma and COPD exacerbations is addressed in international management
guidelines [3,4]. The guidelines also address interventions (such as inhaled corticosteroids)
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that aim to prevent exacerbations, which remain a major cause of morbidity, mortality, and
increased healthcare costs.
Given the beneficial effect that vitamin D supplementation has on acute respiratory
infections (ARI) [5], a growing number of researchers have investigated whether vitamin
D supplements could potentially prevent exacerbations of asthma or COPD [6]. In a 2017
individual participant data (IPD) meta-analysis of all known randomized controlled trials
(RCTs) worldwide, Jolliffe and colleagues demonstrated that vitamin D supplements can re-
duce the risk of asthma exacerbations requiring systemic corticosteroids, especially among
those with baseline serum hydroxyvitamin D (25OHD) levels <25 nmol/L [7]. In contrast,
vitamin D supplementation had no overall effect on the risk of COPD exacerbations among
older individuals [8]. However, a prespecified subgroup analysis did show benefits from
vitamin D supplements among COPD patients with baseline 25OHD levels of <25 nmol/L.
Indeed, all three trials in this IPD meta-analysis reported the same subgroup finding [9–11].
A fourth trial with only 88 participants reported an overall protective effect of vitamin D
supplementation [12].
Nevertheless, questions remain. We performed a large RCT of monthly high-dose
vitamin D supplements (versus placebo) in >5000 older adults in New Zealand. In the
current, prespecified analysis, we investigated the effect of vitamin D supplementation on
the subgroup of participants with asthma or COPD. Specifically, we investigated whether
taking the monthly vitamin D supplement reduced exacerbations overall, or at least in the
subgroup with baseline 25OHD <25 nmol/L.
2. Materials and Methods
Older adults with asthma or COPD came from a large, population-based RCT of
vitamin D supplementation called the Vitamin D Assessment (ViDA) study; this trial
was carried out in Auckland, New Zealand. Full details of the study methods [13], and
the findings on the main outcomes of cardiovascular disease [14], falls/fractures [15],
and ARI [16] have been published. The New Zealand Multi-Region Ethics Committee,
Wellington, approved the trial in October 2010 (MEC/09/08/082), and the main outcomes
were registered with the Australian New Zealand Clinical Trials Registry in April 2011
(ACTRN12611000402943). All participants gave their written informed consent.
The trial investigators invited 5250 people, mainly from family practices in Auckland
(n = 5107) and a small number from community groups (n = 143), who underwent baseline
assessments at the School of Population Health, Tamaki Campus, University of Auckland,
between 5 April, 2011 and 6 November, 2012. The participants were asked questions
about their demographic status, lifestyle (including smoking and physical activity), intake
of vitamin D supplements within the study inclusion criteria (≤600 IU per day if aged
50–70 years; ≤800 IU per day if aged 71–84 years), and past medical history, as informed
by a doctor (including asthma, COPD, and other medical disorders) [13]. The weight (to
the nearest 0.1 kg) and height (to the nearest 0.1 cm) of the participants were measured in
the research clinic.
Spirometry was performed using a KoKo Trek spirometer (nSpire Health; Longmont,
CO, USA) with participants in a seated position, maximally inhaling and then forcibly
exhaling while watching a clock on a computer screen for at least 6 s. Only three efforts
were performed due to time constraints as a result of the large sample size, and to avoid
exhaustion in the elderly participants. All other spirometry recommendations were ful-
filled [17]. The maximum values of forced expiratory volume in 1 s (FEV1; in L), forced
vital capacity (FVC; in L), and their ratio (FEV1/FVC) were derived from the three efforts.
A blood sample was collected and immediately centrifuged for an initial measurement
of corrected serum calcium (those >2.50 mmol/L were excluded). The remaining serum was
stored at −80 ◦C for later measurement of serum 25OHD, using liquid chromatography–
tandem mass spectrometry (API 4000 by SCIEX; Framingham, MA, USA) with 12.7%
interassay coefficient of variation, by a local laboratory participating in the Vitamin D
Nutrients 2021, 13, 521 3 of 12
External Quality Assessment Scheme program (www.deqas.org). The baseline 25OHD was
deseasonalized using standard methods [18].
After the baseline assessment, participants were mailed a run-in questionnaire with a
masked placebo capsule. On return of the questionnaire within four weeks, 5110 partici-
pants were randomized by the study statistician—within random block sizes of 8, 10, or 12,
and stratified by ethnic origin (Māori, Pacific Island, South Asian, European, or other) and
5-year age groups—to receive identical-looking softgel capsules containing either vitamin
D3 (100,000 IU) or placebo. The capsules were provided by Tishcon Corporation (Westbury,
NY, USA).
The capsules were mailed monthly to the homes of the participants, with two capsules
in the first letter (an initial bolus of 200,000 IU vitamin D3 or placebo), and thereafter, one
capsule monthly (100,000 IU vitamin D3 or placebo). Two participants (both from the
placebo arm) withdrew during the follow-up period, which ended on 31 July 2015, so that
2558 participants received vitamin D3 and 2550 received placebo capsules.
New Zealand residents have a unique National Health Index (NHI) number. This
number was used to link each participant to information held by the Ministry of Health
on all dispensed prescriptions from two years before the assessment until the end of the
follow-up on 31 July 2015. This included information on the medication, dose, number of
tablets or volume dispensed, and date of dispensing. Data on all medications used for the
management of asthma or COPD were extracted; these included short-acting β-agonists
(SABA)—inhaled or not inhaled, inhaled long-acting β-agonists (LABA), inhaled short
or long-acting muscarinic antagonists (SAMA or LAMA), inhaled combination SABA
and SAMA agents, inhaled mast cell stabilizers, inhaled corticosteroids (ICS) with or
without LABA, and oral corticosteroids. No participants with asthma or COPD received a
prescription for inhaled orciprenaline, injected bronchodilators (such as aminophylline),
or injected corticosteroids. The Ministry of Health also provided information about any
deaths in the cohort during the follow-up period.
Asthma identification: Participants were asked at their baseline assessment, “Have
you ever been told by a doctor that you have asthma?” Those who answered “Yes” and had
been dispensed a prescription for ICS, SABA, or LABA at any time from 12 months before
randomization to 36 months after, were defined as having asthma and were included in
the current analysis.
COPD identification: Given the well-known underdiagnosis of COPD in the general
population [19,20], spirometry was used to identify participants who had a ratio of forced
expiratory volume in one second (FEV1), divided by forced vital capacity (FVC) of <0.70,
and who had smoked >100 cigarettes in their whole life, regardless of whether they were
current or former smokers. These individuals were defined as having COPD, and were
included in the current analysis.
Primary outcome: Exacerbations of asthma or COPD were identified by any pre-
scription of oral corticosteroids more than 20 days apart for a short period (e.g., several
days), consistent with dosing regimens recommended in international management guide-
lines [3,4], after joint adjudication by two senior clinicians (CAC, LT) who were blinded to
the treatment allocation. Any participants selected according to the above asthma or COPD
identification criteria were excluded if they had medical conditions commonly treated
by oral corticosteroids—e.g., doctor-diagnosed arthritis reported at baseline, except for
osteoarthritis; and doctor-diagnosed inflammatory bowel disease or multiple sclerosis
reported at baseline or in the final end-of-study questionnaire in July 2015.
Figure 1 shows that 1420 participants were selected by the initial screen of either
having doctor-diagnosed asthma or a FEV1/FVC ratio <0.70. After excluding participants
with missing FEV1/FVC ratios, asthma participants not dispensed an inhaled asthma
medication, and COPD participants that had missing information on their smoking status
or those who had never been smokers, 983 participants remained eligible. Of these, a further
208 were excluded for having conditions commonly treated by oral corticosteroids. This
left an analytic sample of 775 participants for the post hoc analysis, with 214 having asthma
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only, 356 having COPD only, and 205 having both conditions; 30 of these participants died
during follow-up. This selection was made without knowledge of the treatment allocation.
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Figure 1. F ow diagr m for selecting par icip nts with asthma or hronic obstructive pulmonary
disease in the ViDA study. COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory
volume in 1 s; FVC = forced vital capacity; SABA = short-acting β-agonist; LABA = long-acting
β-agonist. a Dispensed inhaled corticosteroids, SABA or LABA at any time from 12 months before
randomisation, to 36 months after. b Died by 31 July 2015.
Statistical Analysis
Data were analyzed using SAS (Cary, NC, USA, version 9.4). Chi-square tests and
t-tests were used to compare proportions and means, respectively. The PHREG procedure
was used to calculate hazard ratios (HR) for repeated prescriptions of oral corticosteroids,
using the mean cumulative function overlay for comparison groups, adjusted for covariates.
The mean cumulative function is the average cumulative number of prescriptions at a time
point during follow-up. Effect modification was assessed by the creation of interaction
terms in models that also included the main effects for both variables in the regression
model. Incidence rates were calculated by dividing the number of oral steroid prescriptions
by person-time. p-values were not corrected to account for the multiple hypothesis tests
because, given the known heterogeneity in the effectiveness of vitamin D supplementation
in preventing ARI and asthma or COPD exacerbations [5,7,8], we did not want to miss
any potentially important findings [21]. A two-sided p < 0.05 was considered statistically
significant.
3. Results
The selected sample of participants had a mean (SD) age of 66.6 (8.3) years and 56.4%
were men. Most participants were of European/Other ethnicity (82.7%) and well-educated,
with 49.7% having att nded tertiary education and 48.7% still in paid mployment. Only
12.4% were current tobacco smokers, and a high prop rtio were former smokers (62.7%).
Overall, the mean (SD) FEV1 was 2.16 (0.70) L, FVC was 3.24 (0.96) L, and ratio of FEV1/FVC
was 0.67 (0.10); the observ d bas line 25OHD was 62.5 (23.7) nmol/L.
With regard to disease severity, 74% of participants with asthma only were taking
a long-term controller medication (e.g., inhaled corticosteroids) at baseline. Among all
participants with COPD, the baseline mean (SD) FEV1 was 2.09 (0.69) L, FVC was 3.31
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(0.96) L, and ratio of FEV1/FVC was 0.63 (0.07). Most COPD patients were in GOLD stages
1 and 2: 226 (40%) in stage 1, 271 (48%) in stage 2, 58 (10%) in stage 3, and 6 (1%) in stage 4.
Table 1 compares baseline characteristics between the vitamin D and placebo groups.
There were no between-group differences in distributions of demographic or lifestyle
variables, asthma or COPD status, or in mean levels of spirometry and anthropometry
(p > 0.05). However, participants in the vitamin D group had slightly higher observed and
deseasonalized mean 25OHD concentrations than those in the placebo group (p < 0.05).
Table 1. Baseline comparison of the vitamin D supplemented and placebo groups.
Variable Vitamin D(n = 402)
Placebo
(n = 373) p-Value
Age (years)
0.77
50–59 84 (20.9) 75 (20.1)
60–69 169 (42.0) 152 (40.8)
70–79 128 (31.8) 120 (32.2)
80–84 21 (5.2) 26 (7.0)
Sex–male 227 (56.5) 210 (56.3) 0.96
Ethnicity
0.25
Māori 30 (7.5) 38 (10.2)
Pacific Island 15 (3.7) 22 (5.9)
South Asian 16 (4.0) 13 (3.5)
European/Other 341 (84.8) 300 (80.4)
Education (highest level) a
0.71
Primary school 8 (2.0) 5 (1.3)
Secondary school 198 (49.3) 179 (48.0)
Tertiary 196 (48.8) 189 (50.7)
In paid employment a
0.45
Yes 203 (50.5) 174 (46.8)
No
Retired 172 (42.8) 166 (44.6)
Other 27 (6.7) 32 (8.6)
Tobacco smoking
0.95
Current 50 (12.4) 46 (12.3)
Ex 250 (62.2) 236 (63.3)
Never 102 (25.4) 91 (24.4)
Vigorous physical activity (hours per week) a
0.09
None 149 (38.6) 163 (46.4)
1–2 102 (26.4) 76 (21.7)
>2 135 (35.0) 112 (31.9)
Take vitamin D supplements b 25 (6.2) 31 (8.3) 0.26
Type of asthma/COPD
0.07
Asthma only 106 (26.4) 108 (29.0)
COPD only 200 (49.8) 156 (41.8)
Combined asthma & COPD 96 (23.9) 109 (29.2)
Spirometry, mean (SD)
FEV1 (L) 2.18 (0.71) 2.15 (0.70) 0.53
FEV1, % predicted 78 (19) 79 (19) 0.98
FVC (L) 3.27 (0.98) 3.21 (0.93) 0.37
FVC, % predicted 90 (17) 91 (17) 0.79
Ratio FEV1/FVC 0.67 (0.09) 0.67 (0.10) 0.69
FEV1/FVC, % predicted 86 (12) 86 (11) 0.70
PEF (L/min) 353 (116) 360 (118) 0.43
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Table 1. Cont.
Variable Vitamin D(n = 402)
Placebo
(n = 373) p-Value
Anthropometry, mean (SD)
Height (cm) 168.9 (9.3) 168.6 (9.2) 0.70
Weight (kg) 80.3 (16.2) 80.6 (17.3) 0.81
Body mass index (kg/m2) 28.1 (5.1) 28.3 (5.6) 0.57
Corrected serum calcium, mean (SD) (mmol/L) 2.28 (0.07) 2.27 (0.07) 0.10
25-hydroxyvitamin D (nmol/L)
Observed, mean (SD) 64.5 (23.1) 60.4 (24.2) 0.02
Deseasonalized, mean (SD) 66.7 (22.3) 63.1 (22.9) 0.03
Deseasonalized category
0.03
<25.0 8 (2.0) 10 (2.7)
25.0–49.9 82 (20.4) 109 (29.2)
50.0–74.9 172 (42.8) 134 (35.9)
≥75.0 140 (34.8) 120 (32.2)
Results are number (%) unless otherwise indicated. Abbreviations: FEV1 = forced expiratory volume in 1 s; FVC =
forced vital capacity; PEF = peak expiratory flow rate. a Numbers do not add to total for column because of
missing/don’t know responses. b ≤600 IU per day if aged 50–70 years; ≤800 IU per day if aged 71–84 years.
Table 2 shows the number and incidence rates of oral corticosteroid prescriptions
for all participants, and for demographic and 25OHD categories within the vitamin D
and placebo groups; it also shows HRs for repeated prescriptions in the vitamin D group
compared to the placebo group, adjusted for age, sex, and ethnicity. For all participants in
the analysis, the incidence rate for oral corticosteroid prescriptions was 0.40 per person-year
in the vitamin D group and 0.39 per person-year in the placebo group. The HR was 1.08
(95%CI 0.84–1.39) adjusting for age, sex, and ethnicity, with the mean cumulative function
curves being similar in the two treatment groups (Figure 2).
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All 402 536/1324 0.40 373 469/1218 0.39 1.08 (0.84, 1.39) 0.55
Asthma-COPD category
Asthma only 106 172/352 0.49 108 173/367 0.47 1.18 (0.80, 1.74) 0.41
COPD only 200 176/650 0.27 156 124/494 0.25 1.07 (0.69, 1.67) 0.75
Combined asthma & COPD 96 188/320 0.59 109 172/357 0.48 1.21 (0.78, 1.88) 0.39
Age (years)
50–59 84 155/299 0.52 75 117/270 0.43 1.23 (0.73, 2.07) 0.43
60–69 169 220/550 0.40 152 206/494 0.42 0.99 (0.68, 1.45) 0.97
70–79 128 139/410 0.34 120 108/374 0.29 1.21 (0.73, 2.03) 0.46
80–84 21 22/65 0.34 26 38/80 0.48 0.54 (0.19, 1.52) 0.24
Sex
Male 227 242/744 0.33 210 270/676 0.40 0.83 (0.58, 1.18) 0.30
Female 175 294/580 0.51 163 199/542 0.37 1.46 (1.03, 2.06) 0.03
Ethnicity
Māori 30 41/100 0.41 38 72/127 0.57 0.68 (0.33, 1.42) 0.31
Pacific Island 15 48/53 0.91 22 49/73 0.67 1.37 (0.56, 3.31) 0.49
South Asian 16 33/51 0.65 13 20/43 0.47 1.73 (0.51, 5.92) 0.38
European/Other 341 414/1120 0.37 300 328/976 0.34 1.10 (0.82, 1.46) 0.54
25OHD category (nmol/L) b
<25.0 8 2/27 0.07 10 23/33 0.70 0.11 (0.02, 0.51) 0.005
25.0–49.9 82 152/265 0.57 109 150/360 0.42 1.45 (0.92, 2.30) 0.11
50.0–74.9 172 232/569 0.41 134 168/437 0.38 1.09 (0.76, 1.58) 0.64
≥75.0 140 150/463 0.32 120 128/389 0.33 1.03 (0.62, 1.70) 0.92
Abbreviations: 25OHD = 25-hydroxyvitamin D; 95%CI, 95% confidence interval; COPD = chronic obstructive pulmonary disease; p-Y = person-years. a Adjusted for age, sex, and ethnicity (as appropriate). b
Based on deseasonalized concentrations.
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The incidence rate was lower in both treatment arms for participants with COPD
only, compared to those with asthma only or with combined asthma/COPD. However,
vitamin D had no effect in preventing prescriptions within each of these asthma-COPD
categories, as HRs were not different from 1.00 (p > 0.05). Unexpectedly, the incidence rate
was increased in women given vitamin D compared to placebo (HR 1.46; 95%CI 1.03–2.06;
p for interaction = 0.04). This finding prompted a post hoc analysis to examine for possible
baseline imbalance in lung function, a major predictor of exacerbations. Indeed, among
women, the vitamin D group had worse lung function (e.g., FEV1 % predicted 71% in
vitamin D group vs. 75% in placebo group; p = 0.09). Adjusting for this modest difference
attenuated the original HR from 1.46 to 1.28 (95%CI 0.92–1.79).
When participants were analyzed by baseline 25OHD category, there was a strong
protective effect of vitamin D supplementation in those with deseasonalized 25OHD
<25 nmol/L (HR 0.11, 95%CI 0.02–0.51; p = 0.005; adjusting for age, sex, and ethnicity),
along with a highly significant interaction when comparing the effect of vitamin D in
participants with a baseline 25OHD below and above 25 nmol/L (p for interaction = 0.001).
Further adjustment for baseline FEV1 % predicted had no material impact on the effect
of vitamin D in participants with baseline 25OH <25 nmol/L (HR 0.10; p = 0.004). The
HR reduction was slightly attenuated after adjusting for asthma-COPD status (HR 0.24;
p = 0.06), but the interaction comparing participants with baseline 25OHD below and above
25 nmol/L remained highly significant (p for interaction = 0.002). To explore if there were
potentially important differences in the distribution of baseline variables from participants
with baseline 25OHD <25 nmol/L, we repeated Table 1 in this subgroup; randomization
yielded two similar groups (Supplementary Materials, Table S1). Figure 3 shows the mean
cumulative function for each treatment group by baseline 25OHD category.
Adherence-related data support fidelity to the protocol. For example, 98% of the
775 participants reported taking the study capsule over the study period. In prior publica-
tions, we have documented, in the random subset of participants who underwent multiple
blood testing as part of a safety evaluation, that the observed blood 25OHD levels in the
intervention group increased from approximately 63 nmol/L to 135 nmol/L, consistent
with their vitamin D supplementation, while the 25OHD in the placebo group did not
change [14–16]. Participant retention was also high; for example, 77% of the 775 participants
returned the final monthly questionnaire (July 2015). Lastly, we have previously reported
that the vitamin D intervention did not affect participant-reported adverse events [22,23].
To provide better context for the mostly null RCT findings, we also examined the
observational (noninterventional) association between baseline 25OHD levels and future
risk of asthma or COPD exacerbation in the placebo group only (Supplementary Materials,
Table S2). Participants with asthma (with or without COPD) had significantly increased
HR compared to those with COPD only. The HR also was increased in older participants,
men, and Māori or Pacific Island participants. Despite the limited statistical power, there
was a borderline significant (p = 0.08) increase in HR among participants with baseline
25OHD <25 nmol/L compared to those ≥75 nmol/L.
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4. Discussion
In this post hoc analysis of RCT data from 775 older adults with asthma or COPD,
monthly high-dose vitamin D supplementation (compared to placebo) did not prevent
exacerbations of asthma or COPD. However, in the prespecified subgroup with baseline
25OHD <25 nmol/L, the observed benefit was striking (HR 0.11; 95%CI 0.02–0.51). The con-
sistency of this subgroup finding with prior RCTs focused on either asthma or COPD [7,8]
suggests that the finding is not due to chance alone.
Recent IPD meta-analyses of RCTs on the effects of vitamin D supplementation on
ARI [5], asthma exacerbations [7], and COPD exacerbations [8] provide an excellent
overview of the most relevant RCT literature. Briefly, the ARI meta-analysis showed
an overall benefit of vitamin D supplements, but with substantial heterogeneity accord-
ing to study population and dosing regimen; those who received the most benefit had
baseline 25OHD <25 nmol/L and did not receive bolus dosing [5]. The asthma exacerba-
tion meta-analysis showed an overall benefit, and suggested potentially greater benefit
among those with baseline 25OHD <25 nmol/L [7]. Lastly, the COPD exacerbation meta-
analysis showed no benefit overall, but consistent benefit for those with baseline 25OHD
<25 nmol/L [8]. The current RCT findings are consistent with the results of the asthma
and COPD meta-analyses. The new findings extend the results of earlier studies by having
a much longer duration (average of 3.3 years) and by showing, in the same RCT, that
despite no apparent effect on ARI [16], monthly vitamin D supplementation prevents
asthma/COPD exacerbations among those with vitamin D deficiency.
The apparent discordance between the effects of vitamin D supplementation on
the prevention of ARI per se (avoid bolus dosing for benefit) versus on asthma/COPD
exacerbations (bolus dosing works in specific patient populations) merits further study.
The results raise the intriguing possibility that, while viral respiratory infections trigger
most exacerbations, the beneficial effects of vitamin D on asthma and COPD exacerbations
may involve other effects, such as its anti-inflammatory actions [24]—which may occur
regardless of the exact dosing regimen. Although ViDA is underpowered to look at the
effect of vitamin D supplementation among vitamin D-deficient adults with asthma only,
COPD only, or asthma-COPD overlap, we look forward to contributing our data to future
IPD meta-analyses. Regardless, the emerging differences in how patient population and
dosing regimen can modify the effects of vitamin D supplements suggest that ARI, asthma
exacerbation, and COPD exacerbation outcomes are not truly interchangeable.
Although the ViDA trial suggests that monthly high-dose vitamin D supplementation
is safe, we did note a 46% elevated risk of exacerbation among women assigned to the
vitamin D supplement group (Table 2). We are not aware of any prior observational
or interventional study that suggests that women experience more asthma or COPD
exacerbations at higher levels of circulating 25OHD, or in response to taking vitamin D
supplements [6]. Accordingly, we believe these results are most likely due to chance. We
encourage further research to further investigate this subgroup finding.
The current report has several major strengths, including its study design (randomized,
double-blinded, placebo-controlled trial) with high protocol adherence and the clearly
demonstrated effect of the intervention on blood 25OHD levels [14–16]. Nevertheless,
this RCT, like all RCTs, has potential limitations. First, we remind readers that we tested
one vitamin D regimen (initial bolus, then monthly high-dose boluses) in one population
(older adults); therefore, the relevance of the current study to, for example, daily vitamin
D dosing in children with asthma is unclear. Second, the primary outcome was based
on the prescribing of systemic corticosteroids, which requires clinician recognition of the
exacerbation and prescribing of the appropriate treatment. While it is likely that we missed
exacerbation events, we assume that these events were equally distributed across the two
randomly assigned groups; this would tend to bias results toward the null. Third, despite
starting with 775 participants, the few trial participants with baseline 25OHD <25 nmol/L
(n = 18, 2%) precluded analyses within the asthma only, COPD only, or asthma-COPD
overlap groups. By contributing our trial data to future IPD meta-analyses, we hope to
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compile sufficiently large numbers of participants in these important patient groups to
pursue the issues further.
In summary, although monthly high-dose vitamin D supplementation had no over-
all impact on exacerbations of asthma or COPD in these older adults, we found evi-
dence of probable benefit among those with severe vitamin D deficiency (baseline 25OHD
< 25 nmol/L). While it remains possible that the subgroup finding was due to chance, it
was very similar to results from other vitamin D trials in the literature, particularly those
focused on the prevention of COPD exacerbations [8]. The exact threshold (and mechanism)
for the observed benefit requires further study. To maximize the scientific yield of future
RCTs, we encourage that vitamin D researchers carefully consider the importance of the
trial population, vitamin D dosing regimen, and other factors when both designing and
interpreting the current results, and those from future trials [25].
Supplementary Materials: The following tables are available online at https://www.mdpi.com/20
72-6643/13/2/521/s1: Table S1: Baseline comparison of the vitamin D supplemented and placebo
groups among participants with 25-hydroxyvitamin D < 25 nmol/L. Table S2: Hazard ratios of
oral corticosteroid prescriptions, adjusted for other variables in the table, in the placebo group only
(n = 373).
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